Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
According to the investigator's judgment, there are concomitant diseases that seriously
endanger the patient's safety, or affect the patient's completion of the study (such as
uncontrolled hypertension, diabetes, thyroid disease, etc.);